Skip to main content
Sam-A Pharm. Co. Ltd logo

Sam-A Pharm. Co. Ltd — Investor Relations & Filings

Ticker · 009300 ISIN · KR7009300005 KO Manufacturing
Open in API
Filings indexed 105 across all filing types
Latest filing 2024-03-15 Proxy Solicitation & In…
Country KR South Korea
Listing KO 009300

About Sam-A Pharm. Co. Ltd

https://www.samapharm.co.kr/eng/main201…

Sam-A Pharm. Co. Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of a range of pharmaceutical products. The company specializes in several therapeutic areas, with a primary focus on treatments for respiratory and dermatological conditions. Its portfolio also includes antipyretic, analgesic, and anti-inflammatory medications. Founded in 1945, Sam-A Pharm. operates manufacturing facilities that adhere to high-quality production standards, equivalent to EU-GMP, reflecting its long-standing commitment to improving health and quality of life.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often associated with the Financial Supervisory Service/KRX) sent to shareholders ahead of an Annual General Meeting (AGM). It contains the agenda, proxy solicitation details, and financial statements (balance sheet, income statement, etc.) required for shareholders to make informed voting decisions. While it contains financial data, it is specifically a proxy solicitation document (Proxy Statement) rather than a standalone Annual Report (10-K) or an Earnings Release (ER). Therefore, it falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-15 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Sam-A Pharmaceutical. It outlines the meeting agenda, including the approval of financial statements, director remuneration, and auditor reports. While it contains financial data, it is a proxy statement/notice document intended to inform shareholders of the upcoming meeting and solicit their participation/votes, which fits the definition of a Proxy Solicitation & Information Statement.
2024-03-13 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Sam-A Pharmaceutical. It outlines the date, location, and agenda items (financial statements approval, dividend declaration, and director/auditor remuneration). This document serves as a proxy solicitation or notice of meeting materials provided to shareholders to inform them of the upcoming AGM and the items to be voted upon. Given the specific category for proxy solicitation and information statements, 'PSI' is the most accurate classification.
2024-03-11 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Sam-A Pharmaceutical) announcing a significant change in revenue or profit structure (30% or more). This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to report preliminary financial results before the final audit is completed. Since it provides key financial highlights (revenue, operating profit, net income) and is a specific regulatory disclosure, it falls under the 'Earnings Release' category. FY 2023
2024-02-28 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Sam-A Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share (750 KRW), the total dividend amount, the record date (2023-12-31), and the expected payment date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-28 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Sam-A Pharm Co., Ltd. (삼아제약 주식회사) for the 51st fiscal period, covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial data, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.